By
Drug Target Review2025-05-29T08:30:29
The world’s first translational research center dedicated to urea cycle disorders (UCDs) has been launched in Zürich, marking a significant moment in rare disease innovation.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2025-06-11T14:00:00
Sponsored by Eurofins Discovery
2023-01-05T14:41:33
Sponsored by Cell Signaling Technology
2023-02-16T14:53:10
Sponsored by Cell Signaling Technology
2023-03-07T10:55:58
Sponsored by Agilent
2023-11-24T12:06:45
Sponsored by Quantum-Si
2023-03-08T16:29:20
Sponsored by Bio-Techne
Site powered by Webvision Cloud